Literature DB >> 28031413

Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors.

Monica E Wielgos1, Rajani Rajbhandari1, Tiffiny S Cooper1, Shi Wei2, Susan Nozell1,3, Eddy S Yang4,3,5,6.   

Abstract

HER2+ breast tumors have been shown to express elevated levels of PARP1 protein. Yet, the mechanism by which PARP1 is upregulated in HER2+ breast cancer is unknown. Here, knockdown of HER2 (ERBB2) in HER2+ breast cancer cells resulted in a reduction in PARP1 protein. Conversely, ectopic overexpression of HER2 in a non-HER2-overexpressing cell line resulted in increased PARP1 protein levels. Alterations in HER2 expression had no significant effect on PARP1 transcript levels. Instead, HER2 mRNA status was inversely correlated with let-7a miRNA levels in breast cancer cells. Ectopic expression of let-7a miRNA resulted in downregulation of PARP1 protein, whereas expression of the let-7a anti-miRNA increased PARP1 protein. Furthermore, luciferase assays demonstrate that let-7a regulates PARP1 via its 3'UTR. Importantly, let-7a was significantly lower in human HER2+ breast tumors compared with HER2- breast tumors and inversely correlated with PARP1 protein levels. Finally, HER2+ breast cancer cells exhibited similar cytotoxicity to ectopic let-7a expression as the PARP inhibitor veliparib (ABT-888). Collectively, these results reveal that increased PARP1 expression in HER2+ breast cancers is regulated by the let-7a miRNA, and that let-7a is a potential strategy to suppress PARP1 activity.Implications: This study reports the novel findings that HER2 increases PARP1 protein via suppression of the let-7a miRNA, which regulates the PARP1 3'-UTR. Moreover, HER2 status correlates with high PARP1 and low let-7a in breast cancer clinical specimens. Mol Cancer Res; 15(3); 340-7. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28031413      PMCID: PMC5334184          DOI: 10.1158/1541-7786.MCR-16-0287-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

Review 1.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

2.  Dual roles of PARP-1 promote cancer growth and progression.

Authors:  Matthew J Schiewer; Jonathan F Goodwin; Sumin Han; J Chad Brenner; Michael A Augello; Jeffry L Dean; Fengzhi Liu; Jamie L Planck; Preethi Ravindranathan; Arul M Chinnaiyan; Peter McCue; Leonard G Gomella; Ganesh V Raj; Adam P Dicker; Jonathan R Brody; John M Pascal; Margaret M Centenera; Lisa M Butler; Wayne D Tilley; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2012-09-19       Impact factor: 39.397

3.  Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms.

Authors:  Elena Piskounova; Christos Polytarchou; James E Thornton; Robert J LaPierre; Charalabos Pothoulakis; John P Hagan; Dimitrios Iliopoulos; Richard I Gregory
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

4.  A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation.

Authors:  P O Hassa; M O Hottiger
Journal:  Biol Chem       Date:  1999 Jul-Aug       Impact factor: 3.915

5.  Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Authors:  Todd A Hopkins; Yan Shi; Luis E Rodriguez; Larry R Solomon; Cherrie K Donawho; Enrico L DiGiammarino; Sanjay C Panchal; Julie L Wilsbacher; Wenqing Gao; Amanda M Olson; DeAnne F Stolarik; Donald J Osterling; Eric F Johnson; David Maag
Journal:  Mol Cancer Res       Date:  2015-07-27       Impact factor: 5.852

6.  HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.

Authors:  Somaira Nowsheen; Tiffiny Cooper; James A Bonner; Albert F LoBuglio; Eddy S Yang
Journal:  Cancer Res       Date:  2012-09-15       Impact factor: 12.701

7.  c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.

Authors:  Masanori Kawano; Kazuhiro Tanaka; Ichiro Itonaga; Tatsuya Iwasaki; Hiroshi Tsumura
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

Review 8.  Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.

Authors:  Alice N Weaver; Eddy S Yang
Journal:  Front Oncol       Date:  2013-11-27       Impact factor: 6.244

9.  Biological and clinical significance of PARP1 protein expression in breast cancer.

Authors:  Andrew R Green; Daniela Caracappa; Ahmed A Benhasouna; Alaa Alshareeda; Christopher C Nolan; R Douglas Macmillan; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2014-12-21       Impact factor: 4.872

10.  DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.

Authors:  Alice N Weaver; Tiffiny S Cooper; Marcela Rodriguez; Hoa Q Trummell; James A Bonner; Eben L Rosenthal; Eddy S Yang
Journal:  Oncotarget       Date:  2015-09-29
View more
  4 in total

1.  Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.

Authors:  Ying Shi; Tong Cao; Hua Huang; Chaoqun Lian; Ying Yang; Zhiwei Wang; Jia Ma; Jun Xia
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

2.  An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Authors:  Erica M Stringer-Reasor; Jori E May; Eva Olariu; Valerie Caterinicchia; Yufeng Li; Dongquan Chen; Deborah L Della Manna; Gabrielle B Rocque; Christos Vaklavas; Carla I Falkson; Lisle M Nabell; Edward P Acosta; Andres Forero-Torres; Eddy S Yang
Journal:  Breast Cancer Res       Date:  2021-03-04       Impact factor: 6.466

Review 3.  PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.

Authors:  Luyao Wang; Chao Liang; Fangfei Li; Daogang Guan; Xiaoqiu Wu; Xuekun Fu; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2017-10-08       Impact factor: 5.923

4.  Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection.

Authors:  Sabyasachi Dash; Chandravanu Dash; Jui Pandhare
Journal:  Noncoding RNA       Date:  2021-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.